2. Core Therapeutic Areas and Medical Focus

Biogen Spain S.L. concentrates its resources on a specific set of complex disease states. Its activities are divided into several specialized pillars:

2.1 Multiple Sclerosis (MS)

Multiple Sclerosis remains the historical cornerstone of Biogenâ??s portfolio. Biogen Spain provides one of the industryâ??s most comprehensive ranges of MS therapies, addressing different stages and forms of the disease, including relapsing-remitting MS (RRMS) and primary progressive MS. The companyâ??s work in Spain involves close coordination with neurology departments to optimize patient outcomes through personalized medicine approaches.

2.2 Spinal Muscular Atrophy (SMA)

Biogen revolutionized the treatment landscape for SMA, a rare and often fatal genetic disease affecting muscle strength and movement. Through the introduction of the first approved treatment for SMA in Spain, the company has established a robust infrastructure for the administration of intrathecal therapies and long-term monitoring of pediatric and adult patients.

2.3 Alzheimerâ??s Disease

Biogen Spain is at the forefront of the fight against Alzheimerâ??s disease. The company has invested heavily in the research of amyloid-beta plaque reduction and other mechanisms intended to slow cognitive decline. The Spanish affiliate manages the regulatory navigation and medical education required to bring these complex biological therapies to the Spanish market.

2.4 Amyotrophic Lateral Sclerosis (ALS) and Rare Diseases

The company continues to expand into ultra-rare neuromuscular disorders. Biogen Spain works with specialized centers of excellence across the country to facilitate access to genetic-based therapies for specific subsets of ALS, targeting genetic mutations like SOD1.

3. Product Portfolio

The products marketed and supported by Biogen Spain S.L. represent some of the most advanced biological and chemical entities in modern medicine.

3.1 Multiple Sclerosis Treatments

• Tecfidera (dimethyl fumarate): An oral therapy that has become a standard of care for relapsing forms of MS.
• Vumerity (diroximel fumarate): A next-generation oral treatment designed to offer similar efficacy to Tecfidera with improved gastrointestinal tolerability.
• Tysabri (natalizumab): A high-efficacy monoclonal antibody administered via infusion or subcutaneous injection for patients with highly active MS.
• Plegridy (peginterferon beta-1a): A pegylated interferon that allows for less frequent dosing compared to traditional interferon therapies.
• Avonex (interferon beta-1a): One of the longest-standing therapies in the MS space, used for muscular injection.
• Fampyra (fampridine): A treatment specifically indicated for the improvement of walking in adult patients with MS.

3.2 Neuromuscular and Rare Disease Treatments

• Spinraza (nusinersen): An antisense oligonucleotide (ASO) that was the first therapy approved globally and in Spain for the treatment of Spinal Muscular Atrophy. It is administered via lumbar puncture.
• Qalsody (tofersen): An ASO indicated for the treatment of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

3.3 Alzheimerâ??s Disease Portfolio

• Aduhelm (aducanumab): While its commercial path has been complex, it represented a landmark in anti-amyloid therapy development.
• Leqembi (lecanemab): Developed in partnership with Eisai, this monoclonal antibody targets protofibrils of amyloid-beta and represents the latest advancement in Biogen's Alzheimer's strategy in Europe and Spain.

3.4 Biosimilars

Biogen Spain also operates a significant biosimilars business unit. By offering high-quality biological alternatives to existing off-patent therapies (such as anti-TNF agents used in rheumatology and gastroenterology), Biogen helps the Spanish healthcare system achieve cost savings, which can then be reinvested into innovative treatments. Key biosimilars include: * Benepali (etanercept) * Flixabi (infliximab) * Imraldi (adalimumab)

4. Services and Clinical Research in Spain

Biogen Spain S.L. is more than a sales entity; it is a vital hub for clinical development.

4.1 Clinical Trial Investment

Spain is consistently one of the top countries globally for Biogenâ??s clinical trials. The company partners with major Spanish hospitals (such as Hospital Vall d'Hebron, Hospital Clínic, and Hospital Universitario La Paz) to conduct Phase I, II, and III trials. This provides Spanish patients with early access to experimental therapies and supports the local scientific community.

4.2 Patient Support Programs

The company provides "Biogen Linc," a series of support services designed to help patients manage their chronic conditions. In Spain, these programs focus on treatment adherence, educational resources regarding injection techniques, and psychological support for patients dealing with the burden of neurological decline.

4.3 Medical Education

Biogen Spain S.L. hosts numerous scientific symposiums and educational platforms for Spanish healthcare professionals (HCPs). These initiatives focus on improving the speed of diagnosis for rare diseases and updating neurologists on the latest imaging and biomarker techniques for neurodegenerative conditions.

5. Corporate Social Responsibility and Local Impact

Biogen Spain is active in the local biotechnology ecosystem, participating in associations such as ASEBIO (Spanish Association of Biotechnology Companies) and Farmaindustria. The company focuses on sustainability and equity in healthcare access, working with Spanish authorities to ensure that innovative medicines are integrated into the regional healthcare portfolios of the various Autonomous Communities (Comunidades Autónomas). Their presence in Spain contributes significantly to the "Life Sciences" GDP of the country through high-value employment and ongoing R&D expenditures.